|
| Status |
Public on Aug 04, 2023 |
| Title |
Decitabine disrupts EBV genomic epiallele DNA methylation patterns around CTCF binding sites to increase chromatin accessibility and lytic transcription in gastric cancer [ChIP-seq] |
| Organism |
human gammaherpesvirus 4 |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
To investigate the EBV genome after Decitabine treatment by CTCF ChIP-seq
|
| |
|
| Overall design |
Two EBV positive gastric cancer cell lines were treated with decitabine for 3days
|
| |
|
| Contributor(s) |
Tempera I, Leiberman PM |
| Citation(s) |
37606370, 37889078 |
| |
| Submission date |
Jun 09, 2023 |
| Last update date |
Dec 22, 2023 |
| Contact name |
Sarah Alp |
| E-mail(s) |
salp@wistar.org
|
| Organization name |
The Wistar Institute
|
| Street address |
3601 Spruce Street
|
| City |
Philadelphia |
| State/province |
PA |
| ZIP/Postal code |
19401 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL33481 |
Illumina NextSeq 500 (Human gammaherpesvirus 4) |
|
| Samples (8)
|
|
| This SubSeries is part of SuperSeries: |
| GSE234658 |
Decitabine disrupts EBV genomic epiallele DNA methylation patterns around CTCF binding sites to increase chromatin accessibility and lytic transcription in gastric cancer |
|
| Relations |
| BioProject |
PRJNA982116 |
Less...
More...